The concept of a purinergic signalling system was first proposed by Professor Geoffrey Burnstock over 30 years ago. This includes the cellular responses to purine nucleotides, such as ATP, and nucleosides, such as adenosine, that act as extracellular messengers playing a role through specific purinergic receptors. Levels of extracellular ATP and adenosine depend on cell surface enzymes generically called ectonucleotidases. Since its discovery, purinergic signalling has been shown to mediate a wide range of functions in health and disease, important among them being immunomodulation and inflammation. Recent advances have been made in therapies using purinergic-related drugs in a broad range of pathological conditions such as acute and chronic inflammatory diseases.

We invite researchers to contribute original research articles as well as review articles on the molecular and cellular aspects of purinergic signalling in relation with immune system regulation and inflammation. This includes the study of ligands, receptors, transporters, ectoenzymes, etc. Potential topics include, but are not limited to:

• Mechanisms of nucleotides and nucleosides release (transporters, connexins, etc.)
• Ectonucleotidases in inflammatory diseases and cancer
• Purinergic receptors in inflammatory diseases and cancer
• New technologies for the study of purinergic signalling
• Advances in therapies using purinergic-related drugs in autoimmune diseases
• Purinergic signalling in inflammatory diseases in all systems
• Role of ATP in immunogenic cell death

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/mi/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/mi/psi/ according to the following timetable: